B 220

structure given in first source

Also Known As:

2,3-dimethyl-6-(dimethylaminoethyl)-9-hydroxy-6H-indolo-(2,3-b)quinoxaline; 2,3-dimethyl-N,N-dimethylaminoethyl-5H-indolo(2,3-b)quinoxaline; 9-OH-B220; B-220

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - B 220: 2
    - Indoles: 200
      - B 220: 2

Experts

1.	Boni, Luigi: 1 article (10/2016)
2.	Cassinotti, Elisa: 1 article (10/2016)
3.	Clerici, Federico: 1 article (10/2016)
4.	Frattini, Paolo: 1 article (10/2016)
5.	Roscio, Francesco: 1 article (10/2016)
6.	Scandroglio, Ildo: 1 article (10/2016)

Related Diseases

1.	Rectal Neoplasms (Rectal Cancer) 10/01/2016 - "Group A included 96 and 33 patients, and Group B 220 and 82 for colon and rectal cancers, respectively. "
2.	Papilloma (Papillomatosis) 09/30/1999 - "Moreover, if B-220 treatment was terminated after 20 weeks and TPA treatment continued, papilloma development resumed indicating that initiated tumor cells were still present but were unable to grow with B-220 present. " 09/30/1999 - "Administration of B-220 1 h before TPA promotion resulted in a prolonged latency period of tumor appearance and a significantly reduced (up to 15% of positive controls) papilloma yield at 20 weeks. " 09/30/1999 - "B-220 administration before BPO promotion had no effect on the appearance of BPO induced papillomas or epidermal hyperplasia, suggesting that TPA and BPO promote tumor formation via at least partially different mechanisms. "
3.	Neoplasms (Cancer) 09/30/1999 - "In conclusion, we present evidence that B-220 is a potent inhibitor of mouse skin tumor promotion by TPA, but has little effect on the initiation step or the survival of initiated cells." 09/30/1999 - "If B-220 pretreatment was not given during the first 10 weeks of TPA promotion, incidence at 20 weeks was not reduced but tumor multiplicity was still decreased. " 09/30/1999 - "Moreover, if B-220 treatment was terminated after 20 weeks and TPA treatment continued, papilloma development resumed indicating that initiated tumor cells were still present but were unable to grow with B-220 present. " 09/30/1999 - "Administration of B-220 1 h before TPA promotion resulted in a prolonged latency period of tumor appearance and a significantly reduced (up to 15% of positive controls) papilloma yield at 20 weeks. " 09/30/1999 - "B-220 administration before BPO promotion had no effect on the appearance of BPO induced papillomas or epidermal hyperplasia, suggesting that TPA and BPO promote tumor formation via at least partially different mechanisms. "
4.	Hyperplasia 09/30/1999 - "B-220 administration before BPO promotion had no effect on the appearance of BPO induced papillomas or epidermal hyperplasia, suggesting that TPA and BPO promote tumor formation via at least partially different mechanisms. "